Introducing
Your new presentation assistant.
Refine, enhance, and tailor your content, source relevant images, and edit visuals quicker than ever before.
Trending searches
A Phase 3 Trial of Sebelipase Alfa in Lysosomal Acid Lipase
2
A Phase 3 Trial of Sebelipase Alfa in Lysosomal Acid Lipase Deficiency
CONCLUSION:
Sebelipase alfa therapy resulted in a reduction in multiple disease-related hepatic and lipid abnormalities in children and adults with lysosomal acid lipase deficiency.
SCHOOL UNIVERSITY CATHOLIC
NAME: JIMENA CHAVEZ.
FACEBOOK: JIMENA CHAVE
Name: Jimena Chávez Tarambis
Teacher : Jhon Moscoso
Facebook : Jimena Chávez
Twitter: @Jimena1979Rocio
Correo: jimena1979@hotmail.es
PROS-CONS:
PROS:
Secondary end points included additional disease-related efficacy assessments, safety, and side-effect profile.
CONS:
Substantial disease burden at baseline included a very high level of low-density lipoprotein cholesterol (≥190 mg per deciliter) in 38 of 66 patients (58%) and cirrhosis in 10 of 32 patients (31%) who underwent biopsy.
APPLICATION IN NURSING:
In this multicenter, randomized, double-blind, placebo-controlled study involving 66 patients, we evaluated the safety and effectiveness of enzyme-replacement therapy with sebelipase alfa (administered intravenously at a dose of 1 mg per kilogram of body weight every other weeK.
ISSUE IN ECUADOR:
The placebo-controlled phase of the study was 20 weeks long and was followed by open-label treatment for all patients. The primary end point was normalization of the alanine aminotransferase level.
Definition
Lysosomal acid lipase is an essential lipid-metabolizing enzyme that breaks down endocytosed lipid particles and regulates lipid metabolism. We conducted a phase 3 trial of enzyme-replacement therapy in children and adults with lysosomal acid lipase deficiency, an underappreciated cause of cirrhosis and severe dyslipidemia.